Kathryn Haviland
Chief Executive Officer presso BLUEPRINT MEDICINES CORPORATION
Patrimonio netto: 15 M $ in data 31/03/2024
Posizioni attive di Kathryn Haviland
Società | Posizione | Inizio | Fine |
---|---|---|---|
BLUEPRINT MEDICINES CORPORATION | Director/Board Member | 04/04/2022 | - |
Chief Executive Officer | 04/04/2022 | - | |
President | 04/04/2022 | - | |
Chief Operating Officer | 01/02/2019 | 04/04/2022 | |
Corporate Officer/Principal | 05/01/2016 | 30/01/2019 | |
FULCRUM THERAPEUTICS, INC. | Independent Dir/Board Member | 27/06/2018 | - |
Chairman | 10/01/2022 | - | |
Director/Board Member | 27/06/2018 | 10/01/2022 | |
Harvard Business School Health Industry Alumni Association | Corporate Officer/Principal | - | - |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Corporate Officer/Principal | - | - |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Director/Board Member | 16/10/2023 | - |
Storia della carriera di Kathryn Haviland
Precedenti posizioni note di Kathryn Haviland
Società | Posizione | Inizio | Fine |
---|---|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01/04/2014 | 01/12/2015 |
SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2012 | 01/04/2014 |
PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2007 | 01/06/2012 |
Formazione di Kathryn Haviland
Wesleyan University | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 11 |
Posizioni
Corporate Officer/Principal | 6 |
Director/Board Member | 3 |
Undergraduate Degree | 1 |
Settori
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 4 |
---|---|
SAREPTA THERAPEUTICS, INC. | Health Technology |
PTC THERAPEUTICS, INC. | Health Technology |
BLUEPRINT MEDICINES CORPORATION | Health Technology |
FULCRUM THERAPEUTICS, INC. | Health Technology |
Aziende private | 4 |
---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Harvard Business School Health Industry Alumni Association | |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Commercial Services |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Health Technology |
- Borsa valori
- Insiders
- Kathryn Haviland
- Esperienza